



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

29 September 2026
EMA/MB/185156/2026
Management Board

DRAFT Agenda for the 133rd meeting of the Management Board

Held on 30 September 2026, Virtual (09:00 – 14:00hrs)

Chairperson: Rui Santos Ivo

Item	Title	MB action
1.	Draft agenda	For adoption, EMA/MB/185156/2026*
2.	Declarations of competing interests related to the agenda	Oral report
3.	Minutes from the 132 nd meeting, held on 10-11 June 2026, adopted via written procedure	For information, EMA/MB/134603/2026*
A	Points for automatic adoption	
A.1	Revision of PRAC rules of procedure	For information, EMA/136955/2026; For adoption, EMA/174369/2026*
B	Points for discussion	
B.1	Highlights of the Executive Director	Oral report
B.2	Report from the European Commission	Oral report
B.3	Proceedings for the nomination and appointment of the next EMA Executive Director	For information, EMA/MB/210013/2026; For adoption, EMA/MB/175140/2026*
B.4	Amending Budget 01-2026	For information, EMA/MB/208812/2026; For adoption, EMA/MB/208814/2026*
B.5	Principles on the post-mandate activities of Management Board members	For information, EMA/MB/212080/2026; For discussion, EMA/212081/2026
B.6	EMA Mid-year report 2026 from the Executive Director (January – June 2026)	For information, EMA/MB/209666/2026, EMA/MB/185156/2026*

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Item	Title	MB action
B.7	Clinical Trial Information System (CTIS) development and budget	For discussion and information, EMA/MB/213996/2026, EMA/MB/214025/2026, EMA/214015/2026
B.8	Preparation for implementation of the new EU pharmaceutical legislation (NPL): a) Legislative update (EC) b) Update from the NPL Oversight Group	Oral Report
C	Points for information only**	
C.1	Outcome of written procedures finalised during the period from 04 June to 22 September 2026	For information, EMA/MB/132568/2026*
C.2	Summary of transfers of appropriations in budget 2026	For information, EMA/MB/209789/2026
C.3	22 ND monthly report on <i>ex ante</i> and retroactive evaluation of projects for the period 1 January to 30 June 2026	For information, EMA/MB/165156/2026, EMA/165155/2026
C.4	Network Portfolio Report	For information, EMA/MB/209371/2026, EMA/209377/2026
C.5	Addendum - Inflationary adjustment for rates payable to EDQM for 2027	For information, EMA/MB/162124/2026
C.6	Revised Management Board meeting dates 2026-2027-2028	For information, EMA/MB/44754/2026*
C.7	Revised policy (0072) on the handling of information from external persons on breaches related to the authorisation, supervision and maintenance of human and veterinary medicinal products or other EMA activities	For information, EMA/MB/212408/2026, EMA/102509/2025*
C.8	Report on CTIS and ACT-EU	For information, EMA/MB/212970/2026, EMA/212968/2026
C.9	Update from the Network Data Steering Group (NDSG)	For information, EMA/198789/2026
C.10	Management Board Audit and Risk Groups (MBARG). Minutes of the meeting of 04 September 2026	For information, EMA/MB/202202/2026

* Documents marked with a star * are intended for publication on the external website.

** Documents in *Additional documents for information* section are not intended for discussion unless specifically requested.